This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): Multicomponent Meningococcal Serogroup B Vaccine, 4CMenB (rMenB+OMV), rMenB

Description: Meningococcus B is a highly variable meningococcal subtype that is responsible for approximately 50% of North American cases of invasive meningococcal disease in infants. Existing menigococcal vaccines do not provide coverage against the B subtype. Novartis' meningococcal B vaccine is composed of four distinct antigen components selected for their essential functions in a broad range of MenB strains. Effective vaccines against Neisseria meningitidis serogroups A, C, W-135, and Y have been developed previously, but the close resemblence of serogroup B polysaccharides to human neural cell adhesion molecules reduces the immunogenicity of serogroup B vaccines based on standard capsular polysaccharide strategies. Bexsero instead incorporates surface proteins and outer membrane vesicles.

Deal Structure: GlaxoSmithKline and Novartis
In April 2014, GSK and Novartis entered into a sale agreement under which GSK has agreed to sell, upon completion of the Transaction, the rights to GSKs currently marketed oncology portfolio, related R&D activities and its AKT inhibitor currently in development as well as to grant Novartis preferred partner rights for future commercialisation of GSK oncology products for an aggregate cash consideration of $16 billion. Up to $1.5 billion of this cash consideration depends on the results of the COMBI-d trial, a Phase III study evaluating the safety and efficacy of the combination of Tafinlar (BRAF) and Mekinist (MEK) versus BRAF monotherapy in patients with unresectable or metastatic melanoma.

GSK's marketed Oncology portfolio comprises the rights to GSK's currently marketed oncology assets (Votrient, Arzerra, Promacta/Revolade, Tykerb/Tyverb, Tafinlar, Mekinist, Arranon, Hycamtin, Zofran, Argatroban and Alkeran). Also being sold to...See full deal structure in Biomedtracker

Bexsero News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug